Joseph L. Goldstein
Independent DirectorDr. Joseph L. Goldstein, M.D., has been an Independent Director at Regeneron Pharmaceuticals, Inc. since June 1991. He has been Director of Howard Hughes Medical Institute. Dr. Goldstein was Science Partner and Member of Advisory Board at The Column Group Management LP. Dr. Goldstein is the Professor of Internal Medicine and Molecular Genetics and the Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. He holds following position at University of Texas Southwestern Medical Center at Dallas: Julie and Louis A. Beecherl Distinguished Chair in Biomedical Science, Paul J. Thomas Chair in Medicine and Department of Molecular Genetics. Dr. Goldstein served as a Consultant at Schering Plough, Merck and Amgen. He served as a Member of Scientific Resource Board at Genentech, Inc. and Five Prime Therapeutics, Inc. He serves as a Member of the Science Advisory Boards of NGM Biopharmaceuticals, Inc., GlaxoSmithKline, FivePrime, ARMGO and Cumbre. Dr. Goldstein is a member of the National Academy of Sciences, the National Academy of Medicine and the Royal Society of London. He also serves on the Boards of Trustees of The Rockefeller University and the Howard Hughes Medical Institute. He serves as a Member of Scientific Advisory Board of TriGemX Bio, Inc. (Formerly known as Kallyope, Inc.). Dr. Goldstein is also the Chairman of the Albert Lasker Medical Research Awards Jury and the Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas. He served as Member of the Scientific Advisory Board at ARMGO Pharma, Inc. Dr. Goldstein, together with Dr. Michael S. Brown, has worked for the several years on the genetics and regulation of cholesterol metabolism. Their discovery of the LDL receptor as the major molecule regulating cholesterol metabolism and its genetic disruption in the human disease familial hypercholesterolemia have been recognized by their receipt of numerous awards. He and Dr. Brown discovered the SREBP family of membrane-bound transcription factors and the elucidation of the proteolytic pathway by which the SREBPs become activated to regulate lipid metabolism.
Positions
- Company NameRegeneron Pharmaceuticals, Inc.Stock CodeREGNPositionIndependent DirectorColleagues
- LSLeonard S. SchleiferCo-Founder, President, CEO & Co-Chairman
- GDGeorge D. YancopoulosCo-Founder, President, Chief Scientific Officer & Co-Chairman
- CRChristopher R. FenimoreExecutive VP of Finance & CFO
- JJJoseph J. LaRosaExecutive VP, General Counsel & Secretary
- AJAndrew J. MurphyExecutive VP of Research & Co-Chief Scientific Officer
- GLGeorge L. SingIndependent Director
- CAChristine Ann PoonLead Independent Director
